Results 161 to 170 of about 23,598 (268)

Environmental Enrofloxacin Exposure as a Modifiable Driver of Mitochondria‐Mediated Intestinal Aging and Barrier Dysfunction

Aging Cell, Volume 25, Issue 5, May 2026.
Environmentally relevant enrofloxacin accelerates intestinal aging by impairing epithelial mitochondrial function, disrupting barrier integrity, and reshaping the gut microbiota. Mitochondrial restoration with pyrroloquinoline quinone alleviates hypoxia, inflammation, and gut damage.
Kan Yu, Nengzheng Wang, Xinyi Huang, Yushu Qiu, Xuejian He, Xiaofeng Zhu, Xiaolan Zhou, Peng Yu, Gang Wei, Yan Pi, Ting Ni   +10 more
wiley   +1 more source

Molecular dynamics simulations reveal DNA gate opening mechanisms for M. smegmatis topoisomerase 1A. [PDF]

Biophys J
Sigdel D, Mills M.
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, Volume 183, Issue 9, Page 1747-1778, May 2026.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Characterization of a prokaryotic topoisomerase I activity in chloroplast extracts of maize [PDF]

, 1983
Siedlecki, Janusz, Weissbach, Arthur, Zimmermann, Wolfgang   +2 more
core  

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Direct trapping of the transport-segment DNA by the central domain of type IIA topoisomerases. [PDF]

Sci Adv
Xin Y, Xian R, Liu C, Zhang O, Rao Z, Li X, Chen Y.   +6 more
europepmc   +1 more source

Targeting PRMTs Creates Vulnerability of DNA Double‐Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC

Cancer Science, Volume 117, Issue 5, Page 1273-1285, May 2026.
Our work makes the proof of concept that there is a clinical benefit to target both PRMT1 and PRMT5 to maximize the anti‐tumoral effect of chemotherapy in triple negative breast cancer. ABSTRACT Patients with triple‐negative breast cancer (ER−, PR−, and HER2−) are routinely treated with chemotherapies that induce DNA damage.
Charlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, Louisane Eve, Rania El‐Botty, Laura Sourd, Elodie Montaudon, Ahmed Dahmani, Heloise Derrien, Stéphanie Sentis, Coralie Poulard, Elisabetta Marangoni, Olivier Trédan, Muriel Le Romancer   +13 more
wiley   +1 more source

Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies. [PDF]

Mol Med
Reddy Y, Pai P, Das I, Nayak S, D'Souza NV, Shetty MG, Sundara BK.   +6 more
europepmc   +1 more source

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune ...
Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada, Srinivasu Poondru   +5 more
wiley   +1 more source

Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks. [PDF]

Int J Mol Sci
Osheroff N.
europepmc   +1 more source